Dr. Charles M. Rudin, who presented data from the DeLLphi-304 trial at ASCO 2025, noted that patient-reported outcomes also showed improvements in common symptoms, including dyspnea and cough, with fewer toxicities of grade 3 or higher. Read more
Dr. Patrick Forde recently presented milestone data from the trial that confirms the benefit of neoadjuvant-only chemoimmunotherapy for the treatment of resectable lung cancer. Read more
ZL-1310 earns Fast Track Designation as a potential first-in-class DLL3-targeted ADC for extensive-stage small cell lung cancer. Read more
The US FDA recently granted approval to taletrectinib for ROS1-positive NSCLC and accepted a priority review for lurbinectedin plus atezolizumab for ES-SCLC in the first-line setting. Read more
Dr. Luis G. Paz-Ares reviewed new IMforte trial results at the 2025 ASCO Annual Meeting. Read more
Author Dr. David Spigel says these findings may pave the way for more accurate, biomarker-guided decisions for lung cancer treatment after surgery. Read more
VENTANA MET (SP44) RxDx Assay receives FDA approval as a companion diagnostic for telisotuzumab vedotin-tllv in patients with high c-MET overexpression in NSCLC. Read more
Dana-Farber's Dr. Alice Shaw recently explored various combination strategies that show promise in preventing or delaying resistance in this previously undruggable space. Read more
Drs. Mark Awad and Federica Pecci said recent findings suggest some patients with non-small cell lung cancer may experience survival benefits and disease control even after stopping ICI treatment. Read more
According to recent phase II data, the experimental treatment demonstrated a median overall survival of 24.5 months. Read more